Antibody clustering helps refine lupus prognosis

Area of Science:

• Immunology
• Rheumatology
• Clinical Medicine

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by significant heterogeneity in clinical presentation and disease activity.
• Assessing disease activity is crucial for effective management and treatment strategies in SLE patients.
• Antibody profiles, including anti-double-stranded DNA (anti-dsDNA) and rheumatoid factor (RF) isotypes, are potential biomarkers for disease activity.

Purpose of the Study:

• To investigate the association between specific anti-dsDNA antibody isotypes (IgG, IgM, IgA), rheumatoid factor (RF) isotypes (IgG, IgM, IgA), and IgG anti-C reactive protein (CRP) with systemic lupus erythematosus disease activity (SLEDAI).

Main Methods:

• A cohort of 98 SLE patients (86 women, 12 men) with a mean SLEDAI score of 7.9 +/- 4.1 was analyzed.
• Patients were stratified into four groups based on serum anti-dsDNA antibody isotype intensity levels.
• Levels of IgG, IgM, and IgA anti-dsDNA, RF isotypes, and IgG anti-CRP were measured and correlated with SLEDAI scores.

Main Results:

• Patients with higher IgG anti-dsDNA levels compared to IgM anti-dsDNA exhibited significantly higher SLEDAI scores.
• The presence of IgG or IgM rheumatoid factor (RF) was associated with significantly higher SLEDAI scores compared to its absence.
• IgA RF and IgG anti-CRP levels did not show a significant association with SLEDAI scores.

Conclusions:

• A combination of high-titer IgG anti-dsDNA antibodies and positive IgM RF may serve as a valuable biomarker for identifying patients with more active systemic lupus erythematosus (SLE).
• These specific antibody patterns could aid clinicians in stratifying patients and tailoring treatment for higher SLE disease activity.